Jonathan Schoenfeld Answers: Which Patients Benefit Most from Immunotherapy and Radiation
Jonathan Schoenfeld discusses the patient profile that would benefit best from a combination of radiation and immunotherapy.
Jonathan Schoenfeld, MD, MPhil, MPH, of Dana-Farber Cancer Institute, discusses which patients would benefit most from a combination of immunotherapy and radiation treatment.
Right now, patients with local or locally-advanced disease, or with suppressed immune systems are not thought to be the best candidates for immunotherapy. However, Schoenfeld believes that will change with the advances being made.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
